VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) — Brutus Mining Inc. (“Brutus” or the “Company”) (CSE: BRU) (FSE: ZI3) is pleased to announce the appointments of Gordon Robb and Luke van der Meer, B.Sc., P.Geo., as advisors to the Company (the “Appointments”).

“Gordon and Luke bring the capital markets and technical judgment we want as we plan the Company’s financing strategy and work on the CW Property,” said Christos Doulis, Chief Executive Officer of Brutus. “A company at our stage needs someone who understands how junior exploration companies are financed and followed, and someone who will look at field data and say plainly whether it holds up. We are glad to welcome them.”

Mr. Robb is Chief Executive Officer and a director of ESGold Corp. He has more than a decade of experience in institutional fixed income markets and mining capital markets.

“Brutus has listed, has announced its first financing and has set out where the proceeds go, including the evaluation of new project opportunities. The work now is to close the offerings and keep the Company’s spending and disclosure disciplined. I look forward to working with the board and management on that,” said Mr. Robb.

Mr. Robb has held roles in institutional fixed income markets at ICAP, BGC Partners and TMX Group, and has served as Business Development and Investor Relations Manager of Scottie Resources Corp. He holds a Bachelor of Business Administration in Finance and Economics from Thompson Rivers University.

Mr. van der Meer is a Vancouver-based geological consultant to the Company and has served as its Qualified Person under National Instrument 43-101, reviewing and approving the scientific and technical information in the Company’s news release of September 17, 2026, which announced the engagement of Palliser Exploration Ltd. to carry out a geochemical soil sampling survey of approximately 1,500 samples at the CW Property. The survey is expected to be completed by mid-October 2026.

“The CW Property hosts five documented mineral occurrences and is at an early stage of exploration,” said Mr. van der Meer. “The work now is to understand how those occurrences relate to each other, so that field budgets go to the ground to justify the next step. I look forward to working with the board and management on that.”

Mr. van der Meer holds a Bachelor of Science from the University of Otago in New Zealand. He has served as Vice President Exploration and Qualified Person of Northway Resources Corp., as Vice President Exploration of Longford Exploration Services Ltd., and as Vice President Exploration and Qualified Person of Lodestar Battery Metals Corp. (now Lodestar Metals Corp.). He is the author of the NI 43-101 technical report on the York Harbour Property, Newfoundland, prepared for York Harbour Metals Inc. in 2022. He has also worked with Barrick, Fortescue, HPX, Axiom Exploration Group Ltd., Polar X Limited and VDM Geological Consulting.

Grant of Stock Options

In connection with the Appointments, the Company has granted a total of 225,000 stock options (the “Options”) pursuant to the Company’s Equity Incentive Plan, comprised of 125,000 Options to Mr. Robb and 100,000 Options to Mr. van der Meer. Each Option is exercisable into one common share of the Company at an exercise price of $0.80 per common share for a period of two (2) years from the date of grant.

The Options are governed by the terms of the Company’s Equity Incentive Plan and the Options, and any common shares issued upon the exercise of, are subject to a four month hold period from the date of grant in accordance with the policies of the Canadian Securities Exchange.

About Brutus Mining Inc.

Brutus Mining Inc. (CSE: BRU) (FSE: ZI3) is a Vancouver-based mineral exploration company. Its sole mineral property interest is an option to acquire a 100% interest in the CW Property, five contiguous mineral claims totalling 2,894.56 hectares in the Kamloops Mining Division of British Columbia, approximately 100 kilometres north of Kamloops (the “Property”). The Property hosts five reported MINFILE showings with copper and gold mineralization and is at an early stage of exploration. No mineral resources or mineral reserves have been estimated on the Property.

On Behalf of the Board of Directors

Christos Doulis
Chief Executive Officer, Director
+1 (604) 636-7335
info@brutusmining.com

Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Maxus’, future growth potential for Maxus and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of copper, gold, tungsten, antimony and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Maxus’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the expected benefits of the Appointments. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of copper, gold, tungsten, antimony and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

COLUMBIA, Md., Sept. 30, 2026 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (NASDAQ: REKR) (“Rekor” or the “Company”), a provider of AI-powered roadway intelligence, today announced that the Oregon Department of Transportation (ODOT) has issued an Intent to Award to Rekor for its statewide Connected In-Vehicle Alerts program. The anticipated value is $1.4 million over five years, subject to final contract negotiations and annual renewals after year two.

The planned program would bring Rekor Command® and its Driver Connect feature to a statewide deployment, connecting ODOT’s traffic information directly to drivers. It builds on the Company’s existing Driver Connect deployment within the Las Vegas metropolitan region, which has delivered more than 1.18 million in-vehicle alerts across the Las Vegas metro area.

“Oregon’s intent to award reflects the value of connecting roadway intelligence directly to the drivers who need it,” said Marc Segal, Command Director at Rekor. “Our goal is to help ODOT extend the reach of its traffic information across urban and rural corridors using the vehicle displays and navigation tools drivers already rely on. Rekor’s work in Southern Nevada provides an operating foundation as we move toward a statewide deployment in Oregon.”

Rekor Command® will ingest incident and work zone data from ODOT’s TripCheck traveler information system. Command validates and prioritizes events, and Driver Connect would deliver location-specific alerts to approaching drivers, providing crucial advance notice of roadway hazards. Alert zones would be generated automatically as events enter the system. Under the program, ODOT would transmit safety alerts to vehicles through separate, independent feeds from Rekor and any other selected vendors, helping reach more drivers across Oregon.

Alerts reach drivers through supported factory-installed vehicle displays, navigation apps including Apple Maps and Waze, and electronic logging device platforms for commercial vehicles. Rekor’s partner HAAS Alert would provide vehicle distribution through its Safety Cloud® network. The service requires no roadside hardware or aftermarket devices, and no new app for drivers to download.

The planned service would extend ODOT’s safety messaging beyond fixed roadside signs, including along rural highways where installing and maintaining dynamic message signs is costly. Alerts would operate where cellular coverage and supported vehicle or navigation platforms are available.

For Rekor, the proposed Oregon program represents a multi-year opportunity to expand adoption of Driver Connect and Rekor Command®. The Company expects to extend these capabilities to additional state and regional agencies seeking broader driver alert coverage through active connected vehicle and navigation networks.

About Rekor Systems, Inc.

Rekor Systems, Inc. (NASDAQ: REKR) is a technology company developing trusted data, privacy, security, and intelligence solutions for real-world transportation, public safety, video, and sensor networks. Rekor’s advanced computer vision, machine learning, data security, and media authentication platforms help government agencies, public-safety organizations, transportation authorities, commercial customers, and technology partners transform visual, roadway, and sensor data into trusted, actionable intelligence. Rekor’s solutions are designed to support safer, more efficient mobility, stronger public-safety outcomes, privacy-conscious data practices, operational transparency, and evidentiary integrity.

To learn more, visit Rekor.ai.

Media & Investor Relations Contact

Charles Degliomini
Executive Vice President
Rekor Systems, Inc.
cdegliomini@rekor.ai

Forward-Looking Statements

This press release and its links and attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Rekor Systems, Inc. that involve substantial risks and uncertainties, including particularly statements regarding our future results of operations and financial position, business strategy, prospective products and services, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products and services. These statements involve uncertainties, such as known and unknown risks, and are dependent on other important factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance or achievements we express or imply. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date they are made and are subject to a number of risks, uncertainties and assumptions described under the sections in our Annual Report on Form 10-K for the year ended December 31, 2025 entitled “Risk Factors” and in our subsequent Quarterly Reports on Form 10-Q filed with the SEC. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made in this press release and in other documents we file from time to time with the SEC that disclose risks and uncertainties that may affect our business. The forward-looking statements do not reflect the potential impact of any divestiture, merger, acquisition, or other business combination that had not been completed as of the date of this filing. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on them as predictions of future events. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

COLUMBIA, Md., Sept. 30, 2026 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (NASDAQ: REKR) (“Rekor” or the “Company”), a provider of AI-powered roadway intelligence, today announced that the Oregon Department of Transportation (ODOT) has issued an Intent to Award to Rekor for its statewide Connected In-Vehicle Alerts program. The anticipated value is $1.4 million over five years, subject to final contract negotiations and annual renewals after year two.

The planned program would bring Rekor Command® and its Driver Connect feature to a statewide deployment, connecting ODOT’s traffic information directly to drivers. It builds on the Company’s existing Driver Connect deployment within the Las Vegas metropolitan region, which has delivered more than 1.18 million in-vehicle alerts across the Las Vegas metro area.

“Oregon’s intent to award reflects the value of connecting roadway intelligence directly to the drivers who need it,” said Marc Segal, Command Director at Rekor. “Our goal is to help ODOT extend the reach of its traffic information across urban and rural corridors using the vehicle displays and navigation tools drivers already rely on. Rekor’s work in Southern Nevada provides an operating foundation as we move toward a statewide deployment in Oregon.”

Rekor Command® will ingest incident and work zone data from ODOT’s TripCheck traveler information system. Command validates and prioritizes events, and Driver Connect would deliver location-specific alerts to approaching drivers, providing crucial advance notice of roadway hazards. Alert zones would be generated automatically as events enter the system. Under the program, ODOT would transmit safety alerts to vehicles through separate, independent feeds from Rekor and any other selected vendors, helping reach more drivers across Oregon.

Alerts reach drivers through supported factory-installed vehicle displays, navigation apps including Apple Maps and Waze, and electronic logging device platforms for commercial vehicles. Rekor’s partner HAAS Alert would provide vehicle distribution through its Safety Cloud® network. The service requires no roadside hardware or aftermarket devices, and no new app for drivers to download.

The planned service would extend ODOT’s safety messaging beyond fixed roadside signs, including along rural highways where installing and maintaining dynamic message signs is costly. Alerts would operate where cellular coverage and supported vehicle or navigation platforms are available.

For Rekor, the proposed Oregon program represents a multi-year opportunity to expand adoption of Driver Connect and Rekor Command®. The Company expects to extend these capabilities to additional state and regional agencies seeking broader driver alert coverage through active connected vehicle and navigation networks.

About Rekor Systems, Inc.

Rekor Systems, Inc. (NASDAQ: REKR) is a technology company developing trusted data, privacy, security, and intelligence solutions for real-world transportation, public safety, video, and sensor networks. Rekor’s advanced computer vision, machine learning, data security, and media authentication platforms help government agencies, public-safety organizations, transportation authorities, commercial customers, and technology partners transform visual, roadway, and sensor data into trusted, actionable intelligence. Rekor’s solutions are designed to support safer, more efficient mobility, stronger public-safety outcomes, privacy-conscious data practices, operational transparency, and evidentiary integrity.

To learn more, visit Rekor.ai.

Media & Investor Relations Contact

Charles Degliomini
Executive Vice President
Rekor Systems, Inc.
cdegliomini@rekor.ai

Forward-Looking Statements

This press release and its links and attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Rekor Systems, Inc. that involve substantial risks and uncertainties, including particularly statements regarding our future results of operations and financial position, business strategy, prospective products and services, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products and services. These statements involve uncertainties, such as known and unknown risks, and are dependent on other important factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance or achievements we express or imply. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date they are made and are subject to a number of risks, uncertainties and assumptions described under the sections in our Annual Report on Form 10-K for the year ended December 31, 2025 entitled “Risk Factors” and in our subsequent Quarterly Reports on Form 10-Q filed with the SEC. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made in this press release and in other documents we file from time to time with the SEC that disclose risks and uncertainties that may affect our business. The forward-looking statements do not reflect the potential impact of any divestiture, merger, acquisition, or other business combination that had not been completed as of the date of this filing. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on them as predictions of future events. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

DETROIT, Sept. 30, 2026 (GLOBE NEWSWIRE) — DT Midstream, Inc. (NYSE: DTM) announced today that it has published its annual Corporate Sustainability Report which outlines the company’s environmental, social and governance accomplishments.

The report can be found at dtmidstream.com/sustainability.

“Demand for reliable and affordable energy continues to grow, and we remain focused on developing and operating the infrastructure needed to safely deliver natural gas where it is needed most,” said David Slater, DT Midstream Executive Chairman and CEO. “Sustainability is integral to our long-term strategy and guides how we operate every day—safely, responsibly and with the future in mind.”

About DT Midstream

DT Midstream (NYSE: DTM) is an owner, operator and developer of natural gas interstate and intrastate pipelines, storage and gathering systems, compression, treatment and surface facilities. The company transports clean natural gas for utilities, power plants, marketers, large industrial customers and energy producers across the Southern, Northeastern and Midwestern United States and Canada. The Detroit-based company offers a comprehensive, wellhead-to-market array of services, including natural gas transportation, storage and gathering. For more information, please visit the DT Midstream website at www.dtmidstream.com.

CONTACT: Investor Relations

Todd Lohrmann, DT Midstream, 313.774.2424
investor_relations@dtmidstream.com

DETROIT, Sept. 30, 2026 (GLOBE NEWSWIRE) — DT Midstream, Inc. (NYSE: DTM) announced today that it has published its annual Corporate Sustainability Report which outlines the company’s environmental, social and governance accomplishments.

The report can be found at dtmidstream.com/sustainability.

“Demand for reliable and affordable energy continues to grow, and we remain focused on developing and operating the infrastructure needed to safely deliver natural gas where it is needed most,” said David Slater, DT Midstream Executive Chairman and CEO. “Sustainability is integral to our long-term strategy and guides how we operate every day—safely, responsibly and with the future in mind.”

About DT Midstream

DT Midstream (NYSE: DTM) is an owner, operator and developer of natural gas interstate and intrastate pipelines, storage and gathering systems, compression, treatment and surface facilities. The company transports clean natural gas for utilities, power plants, marketers, large industrial customers and energy producers across the Southern, Northeastern and Midwestern United States and Canada. The Detroit-based company offers a comprehensive, wellhead-to-market array of services, including natural gas transportation, storage and gathering. For more information, please visit the DT Midstream website at www.dtmidstream.com.

CONTACT: Investor Relations

Todd Lohrmann, DT Midstream, 313.774.2424
investor_relations@dtmidstream.com

Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing

CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology indication to transition into GSK’s development pipeline. This program was developed using Wave’s proprietary SpiNA design GalNAc-siRNA.

“The advancement of this development candidate by GSK reflects the recognition of Wave’s differentiated technology, including our best-in-class SpiNA design siRNA,” said Paul Bolno, MD, MBA. “Our SpiNA siRNA compounds demonstrate superior pharmacology, including improved potency, durability and Ago2 loading versus comparator formats. Our collaboration with GSK continues to leverage the versatility of our PRISM™ platform coupled with human genetic insights to advance novel oligonucleotide therapeutics. With this new hepatic program now transitioning to candidate, our collaboration momentum continues as we have three additional programs rapidly advancing towards candidate selection, all leveraging our proprietary PRISM chemistry.”

Wave will receive a $12 million milestone payment for this candidate selection. In addition, Wave is eligible to receive up to $330 – $375 million in development, launch, and commercial milestones for each collaboration program, plus tiered royalties on net sales. Wave is currently advancing three additional collaboration programs towards potential candidate selection.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations for programs we develop using our proprietary SpiNA design GalNAc-siRNA and their best-in-class potential; our potential to earn substantial additional milestone payments and tiered royalties under our GSK collaboration; and our belief supported by data that our SpiNA siRNA compounds demonstrate superior therapeutic properties than comparator formats. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing

CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology indication to transition into GSK’s development pipeline. This program was developed using Wave’s proprietary SpiNA design GalNAc-siRNA.

“The advancement of this development candidate by GSK reflects the recognition of Wave’s differentiated technology, including our best-in-class SpiNA design siRNA,” said Paul Bolno, MD, MBA. “Our SpiNA siRNA compounds demonstrate superior pharmacology, including improved potency, durability and Ago2 loading versus comparator formats. Our collaboration with GSK continues to leverage the versatility of our PRISM™ platform coupled with human genetic insights to advance novel oligonucleotide therapeutics. With this new hepatic program now transitioning to candidate, our collaboration momentum continues as we have three additional programs rapidly advancing towards candidate selection, all leveraging our proprietary PRISM chemistry.”

Wave will receive a $12 million milestone payment for this candidate selection. In addition, Wave is eligible to receive up to $330 – $375 million in development, launch, and commercial milestones for each collaboration program, plus tiered royalties on net sales. Wave is currently advancing three additional collaboration programs towards potential candidate selection.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations for programs we develop using our proprietary SpiNA design GalNAc-siRNA and their best-in-class potential; our potential to earn substantial additional milestone payments and tiered royalties under our GSK collaboration; and our belief supported by data that our SpiNA siRNA compounds demonstrate superior therapeutic properties than comparator formats. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) — Terra Rossa Gold Ltd., (TSXV:TRR, OTCQB:TRGXF) (‘the Company’ or ‘Terra Rossa’), is pleased to provide an update to previously announced investor marketing engagements.

Additional Engagement with Adelaide Capital

The Company is pleased to announce that it has entered into an investor relations agreement (the “Agreement”) with Adelaide Capital Markets (“Adelaide Capital”), a full-service investor relations firm to provide investor relations and consulting services to the Company. Adelaide Capital will assist the Company with investor marketing and communications, including the development of investor materials, coordination of non-deal roadshows, and virtual marketing initiatives.

Under the terms of the Agreement, the Company will pay Adelaide Capital a fee of C$7,500 per month, plus applicable taxes. The Company has not granted Adelaide Capital any stock options or other securities in connection with the Agreement. The Agreement will commence on September 30, 2026 for an initial term of three months ending December 30, 2026, and will continue on a month-to-month basis unless terminated in accordance with its terms.

Adelaide Capital is principally owned by Deborah Honig and is an arm’s-length party to the Company. Adelaide Capital and its employees do not currently own any shares of the Company. The Agreement remains subject to the approval of the TSX Venture Exchange.

Amendment to Access Capital Partners Inc. Engagement

Pursuant to the Company’s announcement on August 25, 2026 of the engagement of Access Capital Partners Inc. (“Access”), the Company and Access have amended the payment terms of the agreement (the “Amended Agreement”), whereby the cash fee of $15,000 to be payable in four monthly instalments of $3,750 plus applicable taxes. The Amended Agreement remains subject to approval of the TSX Venture Exchange.

About Terra Rossa Gold Ltd.

The Company is a gold exploration and development corporation with an experienced mine development team. A local exploration and administration team is in place in Colombia, and the Company also has a local community relations office in the town of Vetas. Current Board and Management is focused on building shareholder value through the advanced exploration and subsequent development of the Vetas gold project.

On Behalf of the Board of Directors

Carter Smith, CEO & Director

T: 604-848-4138 or info@terrarossagold.com

www.terrarossagold.com

X: @terrarossagold

Forward-Looking Information

This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) — Terra Rossa Gold Ltd., (TSXV:TRR, OTCQB:TRGXF) (‘the Company’ or ‘Terra Rossa’), is pleased to provide an update to previously announced investor marketing engagements.

Additional Engagement with Adelaide Capital

The Company is pleased to announce that it has entered into an investor relations agreement (the “Agreement”) with Adelaide Capital Markets (“Adelaide Capital”), a full-service investor relations firm to provide investor relations and consulting services to the Company. Adelaide Capital will assist the Company with investor marketing and communications, including the development of investor materials, coordination of non-deal roadshows, and virtual marketing initiatives.

Under the terms of the Agreement, the Company will pay Adelaide Capital a fee of C$7,500 per month, plus applicable taxes. The Company has not granted Adelaide Capital any stock options or other securities in connection with the Agreement. The Agreement will commence on September 30, 2026 for an initial term of three months ending December 30, 2026, and will continue on a month-to-month basis unless terminated in accordance with its terms.

Adelaide Capital is principally owned by Deborah Honig and is an arm’s-length party to the Company. Adelaide Capital and its employees do not currently own any shares of the Company. The Agreement remains subject to the approval of the TSX Venture Exchange.

Amendment to Access Capital Partners Inc. Engagement

Pursuant to the Company’s announcement on August 25, 2026 of the engagement of Access Capital Partners Inc. (“Access”), the Company and Access have amended the payment terms of the agreement (the “Amended Agreement”), whereby the cash fee of $15,000 to be payable in four monthly instalments of $3,750 plus applicable taxes. The Amended Agreement remains subject to approval of the TSX Venture Exchange.

About Terra Rossa Gold Ltd.

The Company is a gold exploration and development corporation with an experienced mine development team. A local exploration and administration team is in place in Colombia, and the Company also has a local community relations office in the town of Vetas. Current Board and Management is focused on building shareholder value through the advanced exploration and subsequent development of the Vetas gold project.

On Behalf of the Board of Directors

Carter Smith, CEO & Director

T: 604-848-4138 or info@terrarossagold.com

www.terrarossagold.com

X: @terrarossagold

Forward-Looking Information

This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting

On track to launch expanded CNSide testing menu with multiple tests in Q4 2026

HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) — Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”) today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer billings, progress on Medicare coverage of its Tumor Cell Enumeration Test (TCE Test) and the expansion of the CNSide testing menu.

“Over the past few months, we have built the foundation of a reimbursed diagnostics business including clinical evidence, payer contracts, a dedicated billing code, positive CMS Medicare coverage progress, laboratory accreditation and billing infrastructure,” said Russell Bradley, President and General Manager of CNSide Diagnostics. “We are on track to continue that progress across multiple areas of the business for the remainder of the year, and our team is excited about the future of CNSide.”

Third Quarter 2026 CNSide Highlights:

  • Coverage Expansion: CNSide’s lead test, the TCE Test, now stands at 158 million contracted covered lives and is on track to begin 2027 with approximately 200 million covered lives and beneficiaries
  • Medicare Coverage: CNSide received a favorable preliminary CMS pricing decision for CNSide PLA code 0640U with a January 1, 2027 target effective date
  • Payer Billing: In Q3 2026, CNSide billed 222 tests representing $1.55 million of unaudited gross billings, with initial cash collections anticipated in Q4 2026
  • Total Test Volume: CNSide remains on track to meet or exceed an annualized run rate of 1,250 total tests in Q4 2026
  • Cerebrospinal Fluid Test Menu: CNSide is launching the CSF Molecular Profile Test and multiple CNSide Breast Cancer Protein Expression Assays in Q4 2026
  • 2026 Annualized Billing Rate: CNSide is on track to achieve an annualized gross billing run rate of approximately $10 million to $12 million in Q4 2026 based on list pricing, an expanded test portfolio, and continued growth in adoption

Management to Host Conference Call and Webcast Today
Management will host a conference call and webcast today at 8:30 a.m. Eastern Time to provide greater detail on CNSide diagnostics and plans for the remainder of the year. A replay will be available following the call in the Investor Relations section of the Company’s website at ir.cerenome.com.

Date Wednesday, September 30, 2026
Time 8:30 a.m. Eastern Time
Webcast Click here to access the webcast
Dial-in (U.S./Canada) 877-270-2148
Dial-in (International) 412-902-6510
   

Basis of Presentation: Preliminary Results, Gross Billings and Run-Rate Figures
The preliminary third-quarter gross billings figure is based on management’s review of claims submitted through September 30, 2026, is subject to completion of financial close procedures and review by the Company’s independent registered public accounting firm, and may differ materially from final results. “Gross billings” is an operating metric representing charges for CNSide tests submitted to payers at the Company’s list prices; it is not revenue under U.S. GAAP and does not indicate amounts that will be collected. Revenue is recognized under ASC 606 net of contractual allowances and implicit price concessions and is expected to be substantially lower than gross billings. Run-rate figures apply list prices to the Company’s 1,250 total annualized test order goal and historical order rates under the platform’s prior owner, and assume the CNSide CSF Molecular Profile Test and CNSide Breast Cancer Protein Expression Assays launch as planned and are ordered at those rates. CNSide order rates may differ. Existing CPT codes do not establish coverage or payment for these assays on cerebrospinal fluid. Run-rate figures are not forecasts of revenue, gross billings, or collections for any period.

About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/.

About Cerenome
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. For more information, visit https://www.cerenome.com.

Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements other than statements of historical fact are forward-looking statements and may be identified by terms such as “expect,” “potential,” “anticipating,” “planning,” “on track” and similar expressions or the negatives thereof. Such statements are based upon assumptions and assessments made by management in light of their experience and perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding preliminary third-quarter gross billings; the timing and amount of revenue and cash collections; achievement of a 1,250 annualized total test order run rate; annualized gross billings run-rate calculations and the order rates underlying them; the timing of the launches of the CSF Molecular Profile Test and multiple CNSide Breast Cancer Protein Expression Assays; Medicare pricing and its effective date; Medicare and commercial coverage, including the covered-lives target; claim adjudication and reimbursement rates; the timing of revenue guidance; and expectations as to the Company’s future performance. Actual results may differ materially due to a variety of risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

Investor Contact
CORE IR · IR@cerenome.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.